Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-105052
Filing Date
2025-08-07
Accepted
2025-08-07 16:17:00
Documents
66
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atha-20250630.htm   iXBRL 10-Q 2642564
2 EX-31.1 atha-ex31_1.htm EX-31.1 17205
3 EX-31.2 atha-ex31_2.htm EX-31.2 17096
4 EX-32.1 atha-ex32_1.htm EX-32.1 9966
5 EX-32.2 atha-ex32_2.htm EX-32.2 8673
6 GRAPHIC img107090853_0.jpg GRAPHIC 215776
  Complete submission text file 0000950170-25-105052.txt   9098141

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atha-20250630.xsd EX-101.SCH 850962
69 EXTRACTED XBRL INSTANCE DOCUMENT atha-20250630_htm.xml XML 1594184
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

EIN.: 453368487 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39503 | Film No.: 251194286
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)